Trevi Therapeutics, Inc. (TRVI) Income Statement

Revenue is non-existent, so growth analysis focuses on expense trends. R&D spending increased from $8.8M in 2024Q1 to $15.2M in 2026Q2, a 73% rise, indicating accelerated clinical development. The absence of revenue means the company's trajectory is entirely dependent on pipeline milestones, with no near-term top-line visibility.

The cost structure is heavily weighted toward R&D, which accounted for roughly 74% of total operating expenses in 2026Q2. This suggests management is prioritizing pipeline advancement over cost containment, consistent with a clinical-stage biotech. The increase in SG&A, though smaller in absolute terms, indicates growing corporate infrastructure and potential pre-commercialization activities.

With zero revenue, operating leverage is inherently negative; each incremental dollar of R&D or SG&A directly widens operating losses. The operating margin remains deeply negative, and the trend shows no sign of improvement without a commercial product. This underscores the company's dependence on external funding to sustain operations.

This spike in R&D spending likely corresponds to late-stage trial initiation or expansion, which could be a pivotal moment for the company's pipeline. The resulting net loss of $17.8M is the largest in the observed period, indicating a deliberate strategic shift toward advancing its lead candidate. Investors should monitor whether this investment yields clinical data that supports regulatory approval.